Changes in Renal Perfusion During Hemodialysis in Patients with End-stage Renal Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: End-stage Renal Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Changes in Renal Perfusion During Hemodialysis in Patients with End-stage Renal Disease: a Prospective Observational Study
Overview
Residual renal function (RRF) characteristically declines after patients with end-stage renal disease (ESRD) initiate dialysis. Although RRF preservation correlates with improved patient\'s quality of life and survival prospects, poor understanding of the pathophysiology underlying RRF decline limits protection strategies.
Detailed description
Hemodialysis (HD) is the primary renal replacement therapy for patients with end-stage renal disease. However, residual renal function (RRF) characteristically declines after these individuals start dialysis. This loss of RRF not only impacts the adequacy of dialysis and control of complications but also affects the patient\'s quality of life and survival prospects. Due to a lack of clear understanding regarding the pathophysiology underlying this decline in RRF, no effective strategies exist for its preservation at present. The objective of this study is to explore the changes in renal perfusion during hemodialysis in patients with end-stage renal disease, and provide a new idea for protection of RRF. This study was an observational study, and no interventions were performed.
Primary outcome measures
- renal perfusion [Time frame: one day]
Secondary outcome measures (3)
- diastolic blood pressure [Time frame: one day]
- systolic blood pressure [Time frame: one day]
- urine volume [Time frame: 10 months]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years;
- Clinical diagnosis of end-stage renal disease requiring long-term hemodialysis treatment, with dialysis duration ≤ 3 months;
- Urine output \> 500ml/day or GFR \> 3ml/min/1.72m2;
- Signed and dated informed consented is obtained.
Exclusion criteria
- Presence of vascular access dysfunction (blood flow rate \< 180ml/min);
- Severe heart failure;
- Active infection;
- Infectious disease;
- Patients with severe anemia;
- Patients with polycystic kidney disease;
- Expected dialysis duration \< 6 months;
- Pregnancy or lactation women;
- Patients who are participating in other clinical studies, or who have participated in other clinical studies within 3 months prior to enrollment;
- Unwillingness to be followed up or poor adherence to treatment;
- Other circumstances that the investigator considers unsuitable for enrolment.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06587997 · HD-RPC